ESMO Targeted Anticancer Therapies Asia Congress 2026
AI for early-phase clinical trials: from hype to proof of concept
Growing experience suggests that artificial intelligence could potentially transform how cancer research is designed and conducted
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers